PROF vs. KIDS, BBNX, TMCI, CLPT, DCTH, NPCE, SMLR, TCMD, NNOX, and STIM
Should you be buying Profound Medical stock or one of its competitors? The main competitors of Profound Medical include OrthoPediatrics (KIDS), Beta Bionics (BBNX), Treace Medical Concepts (TMCI), ClearPoint Neuro (CLPT), Delcath Systems (DCTH), NeuroPace (NPCE), Semler Scientific (SMLR), Tactile Systems Technology (TCMD), Nano-X Imaging (NNOX), and Neuronetics (STIM). These companies are all part of the "medical equipment" industry.
Profound Medical vs.
Profound Medical (NASDAQ:PROF) and OrthoPediatrics (NASDAQ:KIDS) are both small-cap medical companies, but which is the superior investment? We will contrast the two companies based on the strength of their earnings, community ranking, media sentiment, dividends, profitability, institutional ownership, analyst recommendations, risk and valuation.
OrthoPediatrics received 274 more outperform votes than Profound Medical when rated by MarketBeat users. However, 73.21% of users gave Profound Medical an outperform vote while only 64.42% of users gave OrthoPediatrics an outperform vote.
In the previous week, Profound Medical had 10 more articles in the media than OrthoPediatrics. MarketBeat recorded 12 mentions for Profound Medical and 2 mentions for OrthoPediatrics. OrthoPediatrics' average media sentiment score of 1.71 beat Profound Medical's score of 0.29 indicating that OrthoPediatrics is being referred to more favorably in the news media.
47.9% of Profound Medical shares are owned by institutional investors. Comparatively, 69.1% of OrthoPediatrics shares are owned by institutional investors. 1.5% of Profound Medical shares are owned by company insiders. Comparatively, 31.8% of OrthoPediatrics shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company will outperform the market over the long term.
Profound Medical presently has a consensus target price of $11.50, indicating a potential upside of 135.17%. OrthoPediatrics has a consensus target price of $37.00, indicating a potential upside of 71.69%. Given Profound Medical's stronger consensus rating and higher possible upside, research analysts clearly believe Profound Medical is more favorable than OrthoPediatrics.
OrthoPediatrics has higher revenue and earnings than Profound Medical. OrthoPediatrics is trading at a lower price-to-earnings ratio than Profound Medical, indicating that it is currently the more affordable of the two stocks.
Profound Medical has a beta of 0.68, suggesting that its stock price is 32% less volatile than the S&P 500. Comparatively, OrthoPediatrics has a beta of 1.17, suggesting that its stock price is 17% more volatile than the S&P 500.
OrthoPediatrics has a net margin of -15.00% compared to Profound Medical's net margin of -349.41%. OrthoPediatrics' return on equity of -5.78% beat Profound Medical's return on equity.
Summary
OrthoPediatrics beats Profound Medical on 11 of the 19 factors compared between the two stocks.
Get Profound Medical News Delivered to You Automatically
Sign up to receive the latest news and ratings for PROF and its competitors with MarketBeat's FREE daily newsletter.
New MarketBeat Followers Over Time
This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Media Sentiment Over Time
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Profound Medical Competitors List
Related Companies and Tools
This page (NASDAQ:PROF) was last updated on 4/30/2025 by MarketBeat.com Staff
Buy PROF Stock Free PROF Stock Alerts